Supplementary file 3. Individual scores of the quality assessment

No.	Reference	Study design	Level of evidence	Answer to the quality appraisal question													Total score	Score in percentage	Quality of the study
				1	2	3	4	5	6	7	8	9	10	11	12	13			
1	Scheutz et al[33]	Prevalence	Des-3	V	X	X	V	V	V	V	X	X	-	-	-	-	5/9	55.6	Moderate
2	Levy[34]	Prevalence	Des-2	X	X	V	X	V	V	X	X	V	-	-	-	-	4/9	44.4	Low
3	Kassim et al[35]	Case series	Des-3	X	V	X	V	X	V	V	X	V	V	-	-	-	6/10	60.0	Moderate
4	Zulkifli et al[36]	Analytical cross-sectional	Obs-4	X	X	N/A	V	V	X	X	-	-	-	-	-	-	2/6	33.3	Low
5	Rajeswari et al[37]	Prevalence	Des-3	X	X	X	V	X	V	X	X	X	-	-	-	-	2/9	22.2	Low
6	Jeyakumar[38]	Case series	Des-3	X	X	X	V	X	X	X	V	V	V	-	-	-	4/10	40.0	Low
7	Jamaiah et al[39]	Case series	Des-3	X	X	X	V	V	X	X	X	V	V	-	-	-	4/10	40.0	Low
8	Krahl & Hashim[40]	Prevalence	Des-3	V	V	V	X	V	V	V	V	X	-	-	-	-	7/9	77.8	High
9	Zabedah et al[41]	Prevalence	Des-2	X	X	X	X	V	V	X	X	X	-	-	-	-	2/9	22.2	Low
10	Dony et al[42]	Prevalence	Des-3	V	V	V	X	V	X	X	V	N/A	-	-	-	-	5/8	62.5	Moderate
11	Chandran et al[43]	Case report	Des-4	V	X	V	V	V	N/A	N/A	V	-	-	-	-	-	5/6	83.3	High
12	Nissapatorn et al[44]	Prevalence	Des-3	X	X	V	X	V	V	X	V	N/A	-	-	-	-	4/8	50.0	Low
13	Sobri et al[45]	Case series	Des-3	X	V	V	V	V	X	X	X	V	X	-	-	-	5/10	50.0	Low
14	Leong[46]	Prevalence	Des-3	V	X	X	X	X	V	V	V	X	-	-	-	-	4/9	44.4	Low
15	Sasidharan et al[47]	Prevalence	Des-2	V	V	V	X	V	V	V	V	X	-	-	-	-	7/9	77.8	High

16	Masitah et al[48]	Case series	Des-3	V	X	X	X	X	X	V	X	X	X	-	-	-	2/9	22.2	Low
17	Shailendra & Prepageran[49]	Case report	Des-4	V	X	V	V	V	V	X	V	-	-	-	-	-	6/8	75.0	High
18	Chan et al[50]	Analytical cross-sectional	Obs-4	X	X	N/A	X	X	X	X	-	-	-	-	-	-	0/6	0.0	Low
19	Farhana et al[51]	Case series	Des-3	X	X	X	V	V	V	V	X	V	V	-	-	-	6/10	60.0	Low
20	Chan et al[52]	Analytical cross-sectional	Obs-4	X	X	N/A	X	X	X	X	-	-	-	-	-	-	0/6	0.0	Low
21	Murty[53]	Case report	Des-4	V	V	V	V	N/A	N/A	N/A	X	-	-	-	-	-	4/5	80.0	High
22	Murty et al[54]	Case series	Des-3	X	X	X	V	X	X	V	N/A	V	V	-	-	-	4/9	44.4	Low
23	Mustafa et al[55]	Prevalence	Des-2	V	X	X	X	X	V	V	V	X	-	-	-	-	4/9	44.4	Low
24	Su et al[56]	Analytical cross-sectional	Obs-4	V	X	V	X	X	V	V	-	-	-	-	-	-	4/7	57.1	Moderate
25	Daher et al[57]	Prevalence	Des-2	V	V	X	V	X	V	N/A	V	V	-	-	-	-	6/8	75.0	High
26	Ratnasingam et al[58]	Prevalence	Des-2	X	X	X	X	X	X	X	V	X	-	-	-	-	1/9	11.1	Low
27	Ab Rahman & Abdullah[59]	Case report	Des-4	V	V	V	V	V	V	X	V	-	-	-	-	-	7/8	87.5	High
28	Taib & Baba[60]	Case series	Des-3	X	X	X	V	X	X	V	X	V	X	-	-	-	3/10	30.0	Low
29	Osman et al[61]	Prevalence	Des-3	X	X	X	V	X	V	N/A	V	V	-	-	-	-	4/8	50.0	Low
30	Minhat et al[62]	Prevalence	Des-2	X	X	X	X	X	V	N/A	X	V	-	-	-	-	2/8	25.0	Low
31	Mendelsohn et al[63]	Qualitative	Qual-2	V	V	V	V	V	X	V	V	V	V	-	-	-	9/10	90.0	High
32	Mendelsohn et al[64]	Analytical cross-sectional	Obs-4	V	V	N/A	V	V	X	V	-	-	-	-	-	-	5/6	83.3	High

33	Kwan et al[65]	Case series	Des-3	X	V	X	V	X	X	V	X	X	V	-	-	-	4/10	40.0	Low
34	Santos et al[66]	Prevalence	Des-3	X	X	X	X	V	V	V	V	V	-	-	-	-	5/9	55.6	Moderate
35	Razali et al[67]	Case series	Des-3	V	V	V	V	X	V	V	X	V	V	-	-	-	8/10	80.0	High
36	Elmi et al[68]	Case control	Obs-3	X	V	V	X	V	X	V	X	X	V	-	-	-	5/10	50.0	Low
37	Santos et al[69]	Prevalence	Des-2	X	X	X	X	V	V	V	X	V	-	-	-	-	4/9	44.4	Low
38	William et al[70]	Prevalence	Des-2	V	V	V	X	V	V	V	V	X	-	-	-	-	7/9	77.8	High
39	Siah et al[71]	Prevalence	Des-2	X	X	X	X	X	V	X	X	X	-	-	-	-	1/9	11.1	Low
40	Guinto et al[72]	Scoping review	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	Viijian et al[73]	Analytical cross-sectional	Obs-4	V	X	N/A	X	X	X	X	-	-	-	-	-	-	1/6	16.7	Low
42	Azian et al[74]	Prevalence	Des-2	X	X	X	X	X	V	X	X	X	-	-	-	-	1/9	11.1	Low
43	Sahimin et al[75]	Prevalence	Des-2	X	X	X	X	X	V	V	V	X	-	-	-	-	3/9	33.3	Low
44	Noh et al[76]	Prevalence	Des-2	X	X	X	X	X	V	X	V	X	-	-	-	-	2/9	22.2	Low
45	Kamaludin & How[77]	Analytical cross-sectional	Obs-4	V	X	N/A	X	X	V	V	-	-	-	-	-	-	3/6	50.0	Low
46	Min et al[78]	Prevalence	Des-3	V	V	V	X	V	X	X	V	N/A	-	-	-	-	5/8	62.5	Moderate
47	Woh et al[79]	Prevalence	Des-3	X	X	X	V	V	V	X	V	X	-	-	-	-	4/9	44.4	Low
48	Tanabe et al[80]	Mixed method	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
49	Ratnalingam et al[81]	Prevalence	Des-2	V	X	X	X	V	V	X	X	X	-	-	-	-	3/9	33.3	Low

50	Woh et al[82]	Prevalence	Des-2	X	X	X	X	X	V	X	V	X	-	-	-	-	2/9	22.2	Low
51	Noor & Shaker[83]	Analytical cross-sectional	Obs-4	V	X	V	V	V	V	V	-	-	-	-	-	-	6/7	85.7	High
52	Noordin et al[84]	Prevalence	Des-3	X	X	X	X	V	V	X	V	X	-	-	-	-	3/9	33.3	Low
53	Sahimin et al[85]	Prevalence	Des-2	X	X	X	V	X	V	V	V	X	-	-	-	-	4/9	44.4	Low
54	Labao et al[86]	Prevalence	Des-3	X	X	X	X	V	V	V	V	V	-	-	-	-	5/9	55.6	Moderate
55	Shaw et al[87]	Randomised controlled trial	Exp-2	X	X	X	X	X	X	X	X	V	V	V	V	X	4/13	30.8	Low
56	Rahman et al[88]	Case control	Obs-3	X	V	V	X	V	X	V	X	V	V	-	-	-	6/10	60.0	Moderate
57	Sahimin et al[89]	Prevalence	Des-2	X	X	X	V	X	V	V	V	X	-	-	-	-	4/9	44.4	Low
58	Nwabichie et al[90]	Prevalence	Des-2	V	V	X	X	V	V	V	V	V	-	-	-	-	7/9	77.8	High
59	Jeffree et al[91]	Case control	Obs-3	X	V	V	X	V	X	X	V	V	V	-	-	-	6/10	60.0	Moderate
60	Zerguine et al[92]	Analytical cross-sectional	Obs-4	X	V	V	X	X	V	V	-	-	-	-	-	-	4/7	57.1	Moderate
61	Ya'acob et al[93]	Randomised controlled Trial	Exp-2	X	X	V	X	X	X	V	X	X	V	V	V	X	5/13	38.5	Low
62	Chuah et al[9]	Qualitative	Qual-2	V	V	V	V	V	X	V	X	V	V	-	-	-	8/10	80.0	High
63	Loganathan et al[94]	Qualitative	Qual-2	X	V	V	V	V	X	V	V	V	V	-	-	-	8/10	80.0	High
64	Rahman et al[95]	Prevalence	Des-3	X	X	X	X	V	X	X	V	V	-	-	-	-	3/9	33.3	Low
65	Siah et al[96]	Qualitative	Qual-3	X	V	X	V	V	X	X	X	V	V	-	-	-	5/10	50.0	Low
66	Sahimin et al[97]	Prevalence	Des-2	X	X	X	V	X	V	X	V	X	-	-	-	-	3/9	33.3	Low

67	Chuah et al[98]	Qualitative	Qual-2	V	V	V	V	V	X	V	X	V	V	-	-	-	8/10	80.0	High